Mild cognitive impairment, early dementia Mental and Behavioural Disorders
Conditions
Interventions
Clove (Syzygium aromaticum) liquid extract: 42 mg/day, of which beta-caryophyllene 37.8 mg, terpenes 4.2 mg
- Myrrh liquid extract: 24 mg/day, of which furanodienes 19.2 mg, terpenes 4.8 mg
- Boswelli
Sponsors
Pharmaceutica San Marco
Eligibility
Sex/Gender
All
Age
65 Years to 85 Years
Inclusion criteria
Inclusion criteria: Patients aged 65–85 years with cognitive impairment ranging from mild cognitive impairment to mild/moderate dementia, as assessed by the Clinical Dementia Rating (CDR) scale (scores 0.5–2)
Exclusion criteria
Exclusion criteria: 1. CDR scores 2 2. Recent stroke or transient ischemic attack 3. Unstable heart disease 4. Renal and hepatic failure 5. Oncologic patients 6. Inability to provide consent or refusing to provide informed consent
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Depressive state measured using Zung score at baseline, 3 months, 6 months;Neurodegenerative biomarkers measured using light neurofilaments -ELISA method at baseline, 3 months, 6 months;Neurodegenerative biomarkers measured using amyloid beta-ELISA method at baseline, 3 months, 6 months;Neurodegenerative biomarkers measured using pTAU-ELISA method at baseline, 3 months, 6 months | — |
Primary
| Measure | Time frame |
|---|---|
| Psychometric assessments measured using Clinical Dementia Rating (CDR) at baseline, 3 months, 6 months;Psychometric assessment measured using mini mental state examination (MMSE) at baseline, 3 months, 6 months | — |
Countries
Italy
Contacts
Public ContactLuigia Trabace
Outcome results
None listed